Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialMarc A. Pfeffer, Bertram Pitt, Brian Claggett et al.|Circulation|2014Cited by 1k
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D. Solomon, Subodh Verma, Sanjiv J. Shah et al.|New England Journal of Medicine|2024Cited by 693
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trialMichael E. Nassif, Mikhail Kosiborod, Sheryl L. Windsor et al.|Nature Medicine|2021Cited by 599
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionScott D. Solomon, Marc A. Pfeffer, Brian Claggett et al.|European Heart Journal|2015Cited by 524
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection FractionMihai Gheorghiade, Stephen J. Greene, Javed Butler et al.|JAMA|2015Cited by 389